logo-loader
Ergomed PLC

Ergomed plc - Ergomed to present at the German Equity Forum 2017

RNS Number : 5298X
Ergomed plc
27 November 2017
 

PRESS RELEASE

 

 

Ergomed to present at the German Equity Forum 2017

 

London, UK - 27 November 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a specialised pharmaceutical services and drug development company, today announces its attendance at the German Equity Forum 2017 (Deutsches Eigenkapitalforum) which will be taking place at The Sheraton Frankfurt Airport Hotel & Conference Center in Frankfurt am Main, Germany, from 27 to 29 November.

 

Dr. Miroslav Reljanovic, Executive Vice-Chairman, will be presenting at 11:00am CET on 27 November.

 

ENDS

 

 

 

Enquiries:

 

Ergomed plc

Tel: +44 (0) 1483 503205

Miroslav Reljanovic (Executive Vice Chairman)


Stephen Stamp (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)


James Black (Joint Broker)




N+1 Singer

Tel: +44 (0) 20 7496 3000

Alex Price (Joint Broker)




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Philippa Gardner

ergomed@consilium-comms.com



MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke


 

 

About Ergomed

 

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUNVARBNAAUUA
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

Ergomed in robust shape to keep delivering

Jonathan Curtain, the new CFO of Ergomed PLC (AIM:ERGO, ETR:2EM), discussed his background and the company's growth prospects in an interview with Proactive London. The specialist services provider to the pharmaceutical industry focuses on growth areas like rare diseases and...

on 17/5/23

2 min read